VC Deals Analysis: Only Christmas Miracle Will Close Gap
As the end of the year approaches, medtech venture financing activity looks to have picked up in November to be on par with the previous year's level – but not enough to bridge the gap in annual performances.
You may also be interested in...
A company set up five years ago is now worth billions and new funding keeps pouring into the white hot genome testing area in China, despite some observers warning that valuations are unjustified and the bubble is fit to burst.
Republican Congress, Trump Policies May Seek To 'Undo' FDA Device Safety Guidances; LDT Plan First To Go
Emboldened by a Republican victory in the White House, GOP members of Congress are already putting the screws on federal agencies to back off on health and safety regulations and guidances for products, with some success – for example, FDA's Nov. 18 decision to shelve its proposed laboratory developed test guidance in final form seems to be a response to the new political reality in DC.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.